NEXGEL Share Price

NXGL

US65344E1073

Market Closed - Nasdaq 21:00:00 07/10/2026 BST			5-day change	1st Jan Change
0.1772 ^USD	+2.49%		+2.55%	-88.99%

09-24	NEXGEL, Inc. - Special Call
08-24	Maxim Downgrades NexGel to Hold From Buy	MT

Last Transcript: NEXGEL

NEXGEL, Inc. - Special Call

09-24

More transcripts

Analysts' recommendations: NEXGEL

08-24

Maxim Downgrades NexGel to Hold From Buy

More recommendations

Managers and Directors: NEXGEL

Manager	Title	Age	Since
Brian Kieser CEO	Chief Executive Officer	59	20/08/2026
Ian Blackman DFI	Director of Finance/CFO	58	26/04/2026
Gregory J. Robb COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Jerome Zeldis BRD	Director/Board Member	76	31/03/2020
Steven Glassman CHM	Chairman	61	-
Steven Ciardiello BRD	Director/Board Member	55	30/07/2025

More insiders

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Companyâ€™s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
07/10/26	US$0.1772	+2.49%	637,479
06/10/26	US$0.1729	+1.71%	321,073
05/10/26	US$0.1700	-2.30%	291,315
02/10/26	US$0.1740	-2.52%	222,912
01/10/26	US$0.1785	+3.30%	310,947

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.1772

Average target price

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - NEXGEL

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NEXGEL

Company calendar

Market Cap	1.73M 1.54M 1.44M 1.31M 2.46M 167M 2.48M 17.3M 6.76M 84.98M 6.48M 6.34M 273M	P/E 2026 *	-0.19x	P/E 2027 *	-0.81x
Enterprise Value	1.73M 1.54M 1.44M 1.31M 2.46M 167M 2.48M 17.3M 6.76M 84.98M 6.48M 6.34M 273M	EV / Sales 2026 *	0.11x	EV / Sales 2027 *	0.07x
Free-Float	85.98%	Yield 2026 *	-	Yield 2027 *	-

09-24	NEXGEL, Inc. - Special Call
08-24	Maxim Downgrades NexGel to Hold From Buy	MT
08-20	Nexgel, Inc. Forms Special Committee to Oversee Comprehensive Strategic Review and Value Creation	CI
08-20	Nexgel, Inc. Announces CEO Changes, Effective August 21, 2026	CI
08-20	Nexgel, Inc. Announces Special Committee, Effective August 21, 2026	CI
08-20	NexGel Files to Register 15.25 Million Shares From Note Conversions	MT
08-17	NEXGEL, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-02	Nexgel, Inc. Announces Resignation of Scott Henry as Member of Board of Directors, Effective July 1, 2026	CI
05-19	NEXGEL, Inc. Reports Positive Data From Randomized Single-Center IRB Study To Evaluate The Effectiveness And Safety Of A Hydrogel Laser Treatment Patch In Laser Hair Removal	CI
05-15	NEXGEL, Inc., Q1 2026 Earnings Call, May 15, 2026
05-14	NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	NEXGEL, Inc. announced that it has received $1.21 million in funding	CI
05-13	Nexgel appoints Dave Hazard as vice president of sales for Bionx Surgical	RE

09-23	NEXGEL Announces Dial-In Details for Investor Update Call	AQ
09-16	NEXGEL Announces Date for Investor Update Call	AQ
08-20	NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE	AQ
08-17	NEXGEL Reports Second Quarter 2026 Financial Results	AQ
06-05	NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th -18th	AQ

1 day	+2.49%
1 week	+2.55%
Current month	+2.55%
1 month	-44.01%
3 months	-67.77%
6 months	-71.00%
Current year	-88.99%

1 week	0.16	0.19
1 month	0.16	0.3
Current year	0.16	1.9
1 year	0.16	2.89
3 years	0.16	5.1
5 years	0.16	5.1
10 years	0.16	5.1

NEXGEL Share Price

Stocks

NXGL

US65344E1073

Valuation: NEXGEL

Chart: NEXGEL

Latest news: NEXGEL

Last Transcript: NEXGEL

Analysts' recommendations: NEXGEL

Press Releases: NEXGEL

Quotes and Performance

Price Extremes

Managers and Directors: NEXGEL

Latest insider transactions

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/07/26	Adam Levy	Free	Chief Executive Officer	160,000	1.7344%
08/06/26	Adam Levy	Sell	Chief Executive Officer	-3,000	0.0329%
01/06/26	Adam Levy	Sell	Chief Executive Officer	-2,000	0.0219%

	2026 *	2027 *
Net sales	15.79M 14.11M 13.16M 11.95M 22.51M 1.53B 22.68M 158M 61.78M 777M 59.27M 57.99M 2.5B	24.27M 21.68M 20.23M 18.37M 34.61M 2.35B 34.86M 243M 94.97M 1.19B 91.1M 89.13M 3.84B
Net income	-8.33M -7.44M -6.94M -6.31M -11.87M -806M -11.96M -83.41M -32.59M -410M -31.26M -30.59M -1.32B	-2.31M -2.07M -1.93M -1.75M -3.3M -224M -3.32M -23.16M -9.05M -114M -8.68M -8.49M -366M
Net Debt	-	-

Markets		Quality
Nasdaq	NXGL	Delayed
CBOE	NXGL	Real-time